Evidence map›Paper›PMID 27401941›Full record

ReviewExpert opinion on drug delivery2017

Nanoparticles for imaging and treatment of metastatic breast cancer.

Qingxin Mu, Hui Wang, Miqin Zhang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Expert opinion on drug delivery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 1 synthesis or guideline pooled it, 118 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Impact of Nanomedicine in Women's Metastatic Breast Cancer.Small (Weinheim an der Bergstrasse, Germany) · 2024
    Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Theranostics for Triple-Negative Breast Cancer.Diagnostics (Basel, Switzerland) · 2023
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Qingxin Mua Department of Materials Science and Engineering , University of Washington , Seattle , WA , USA.
Hui Wanga Department of Materials Science and Engineering , University of Washington , Seattle , WA , USA.
Miqin Zhanga Department of Materials Science and Engineering , University of Washington , Seattle , WA , USA.
University of Washington · US

Funding

Multifunctional nanoparticles to improve treatment of human glioblastomaR01CA161953 · NCI · UNIVERSITY OF WASHINGTON · PI ZHANG, MIQIN · 2013 to 2017
$1.7M
Nanotechnology and Physical Science Training Program in Cancer ResearchT32CA138312 · NCI · UNIVERSITY OF WASHINGTON · PI ZHANG, MIQIN · 2009 to 2013
$1.5M
NCI NIH HHS R01 CA161953NCI NIH HHS T32 CA138312
6 · The paper itself

Abstract

introductionMetastatic breast cancer is one of the most devastating cancers that have no cure. Many therapeutic and diagnostic strategies have been extensively studied in the past decade. Among these strategies, cancer nanotechnology has emerged as a promising strategy in preclinical studies by enabling early identification of primary tumors and metastases, and by effective killing of cancer cells. Areas covered: This review covers the recent progress made in targeting and imaging of metastatic breast cancer with nanoparticles, and treatment using nanoparticle-enabled chemo-, gene, photothermal- and radio-therapies. This review also discusses recent developments of nanoparticle-enabled stem cell therapy and immunotherapy. Expert opinion: Nanotechnology is expected to play important roles in modern therapy for cancers, including metastatic breast cancer. Nanoparticles are able to target and visualize metastasis in various organs, and deliver therapeutic agents. Through targeting cancer stem cells, nanoparticles are able to treat resistant tumors with minimal toxicity to healthy tissues/organs. Nanoparticles are also able to activate immune cells to eliminate tumors. Owing to their multifunctional, controllable and trackable features, nanotechnology-based imaging and therapy could be a highly potent approach for future cancer research and treatment.

Indexed as

NanoparticlesBreast NeoplasmsDrug CarriersFemaleHumansImmunotherapyNanotechnologyDrug Carriersbreast cancercancer stem cellsdrug deliveryimagingimmunotherapymetastasisNanoparticles

Identifiers

PMID27401941
PMCPMC5835024
OpenAlexW2460584341

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.